Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12...678910111213141516...15251526»
  • ||||||||||  Journal:  Primary Intraosseous Spindle Cell Rhabdomyosarcoma: A Case Report in an Unusual Location. (Pubmed Central) -  Jun 7, 2024   
    Initially, osteosarcoma was the primary diagnostic consideration based on distal long bone location, patient age, and evidence of osteoid formation. Distinction between the two entities may be nearly impossible on morphologic grounds alone, which presents a diagnostic pitfall without molecular or extensive immunoprofiling data.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Natural melanin nanoparticles (MNPs) extracted from Sepia officinalis: A cost-effective, chemo-photothermal, synergistic nanoplatform for osteosarcoma treatment. (Pubmed Central) -  Jun 6, 2024   
    This work reports a novel drug delivery nanoplataform made of Natural Melanin Nanoparticles (MNPs), obtained from Sepia officinalis ink, with 99% incorporation efficiency of doxorubicin (Dox) without the use of non-toxic solvents...On the contrary, when natural MNPs loaded with Dox (Dox-MNPs) were placed in contact with the SaOs-2 cells and were simultaneously receiving NIR light it was observed a 93% reduction in cancer cells in 48?h, revealing a synergistic effect between chemotherapy and phototherapy. To our knowledge this is the first time that natural MNPs extracted from Sepia officinalis were tested on an osteosarcoma cell line as chemo-photothermal agent, showing these NPs are an effective, cost-effective, reproducible, non-toxic nanoplatform for osteosarcoma treatment using combined effects.
  • ||||||||||  Journal, HEOR:  Understanding quality of life's challenges in sarcoma patients: A mixed-methods study. (Pubmed Central) -  Jun 6, 2024   
    Large prospective studies will help define clinical management for geriatric patients. The results underscore the significance of delivering care that enhances the quality of life for sarcoma patients, addressing both their physical and psychosocial needs, and providing personalized support throughout all stages of the disease.
  • ||||||||||  Journal:  A case of pseudo-Kaposi sarcoma with chronic limb-threatening ischemia. (Pubmed Central) -  Jun 6, 2024   
    This is a rare case of PKS with CLTI complicated with AVM. As there is currently no established consensus on the treatment of PKS, the approach to treatment strategy should be tailored to the specific condition of each patient.
  • ||||||||||  Journal:  Intrinsic epigenetic state of primary osteosarcoma drives metastasis. (Pubmed Central) -  Jun 6, 2024   
    This data demonstrates that metastatic potential is intrinsically present in primary metastatic tumors, with cellular chromatin profiles further adapting for successful dissemination, migration, and colonization at the distal site. Implications: Our study demonstrates that metastatic potential is intrinsic to primary metastatic osteosarcoma tumors, with chromatin profiles further adapting for successful dissemination, migration and colonization at distal metastatic site.
  • ||||||||||  Journal:  Granulocytic neoplasm suggestive of primary myeloid sarcoma in 3 dogs. (Pubmed Central) -  Jun 6, 2024   
    Blood and bone marrow infiltration were not detected at initial diagnosis, excluding acute myeloid leukemia. The behavior of these tumors was aggressive, resulting in poor clinical outcomes, even when chemotherapy was attempted.
  • ||||||||||  Journal, IO biomarker:  Emerging therapies in Ewing sarcoma. (Pubmed Central) -  Jun 6, 2024   
    The behavior of these tumors was aggressive, resulting in poor clinical outcomes, even when chemotherapy was attempted. Close international collaboration between clinicians and biologists will allow us to prioritize promising emerging therapies and develop biomarkers to facilitate their incorporation into standard of care and more rapidly translate into benefit for Ewing sarcoma patients.
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene, Ogsiveo (nirogacestat) / SpringWorks Therap
    Journal:  Active surveillance and emerging medical treatment options for desmoid: when and for whom? (Pubmed Central) -  Jun 6, 2024   
    Active surveillance has solidified its position as the primary management approach for desmoid tumors, validated by three robust prospective studies. Three recent randomized trials explored medical treatment for progressive or recurrent desmoid tumors, revealing promising clinical activities.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions. (Pubmed Central) -  Jun 6, 2024   
    Even when direct comparisons between PD1/PDL-1 inhibitor-based combinations and single agents have not been performed yet in sarcoma, some combinations appear promising. Studies controlling heterogeneity by biomarker or histotype selection contribute to an increase in efficacy or knowledge crucial for future comparative trials.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
    Journal:  New targeted therapies in liposarcoma: state of art and future perspectives. (Pubmed Central) -  Jun 6, 2024   
    Studies controlling heterogeneity by biomarker or histotype selection contribute to an increase in efficacy or knowledge crucial for future comparative trials. Although preliminary, results of recently published and ongoing examined clinical trials will hopefully be translated in clinical practice in the next future, leading the way to future research in this rare disease.
  • ||||||||||  Biomarker, Journal:  Sarculator: how to improve further prognostication of all sarcomas. (Pubmed Central) -  Jun 6, 2024   
    Currently, clinical variables continue to be the most significant and effective factors in terms of predicting outcomes in patients with STS. This review firstly introduces the rationale for developing and employing nomograms such as Sarculator, secondly, reflects on some of the latest and ongoing methodological refinements, and provides future perspectives in the field of prognostication of sarcomas.
  • ||||||||||  Biomarker, Clinical, Review, Journal, Circulating tumor DNA, Stroma, Metastases:  Monitoring advanced gastrointestinal stromal tumor with circulating tumor DNA. (Pubmed Central) -  Jun 6, 2024   
    The dynamic field of ctDNA technologies is rapidly evolving and holds significant promise for research. Several trials have successfully validated the clinical utility of ctDNA in metastatic GIST, laying the foundations for its prospective integration into the routine clinical management of GIST patients.
  • ||||||||||  MRTX1133 / BMS
    Preclinical, Review, Journal:  Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance. (Pubmed Central) -  Jun 6, 2024   
    Of interest, the non-covalent KRASG12D targeting inhibitor MRTX-1133 has shown promising results in humanized pancreatic cancer mouse models and is seemingly making its way from bench to bedside...Finally, the next generation of KRAS mutant-specific and pan-RAS tri-complex inhibitors have revolutionized RAS drug discovery. This review will give a structural biology perspective on the current generation of KRAS inhibitors through the lens of emerging secondary mutations and acquired resistance.
  • ||||||||||  imatinib / Generic mfg.
    Journal, Metastases:  Metastatic Fibrosarcomatous Transformation of Dermatofibrosarcoma Protuberans With Lung Metastasis: A Case Report. (Pubmed Central) -  Jun 6, 2024   
    Molecularly, DFSP is defined by a COL1A1-PDGFB fusion transcript that is targetable with imatinib therapy...Overall, this case underscores the challenges in diagnosing and managing aggressive sarcomas like fibrosarcomatous DFSP, emphasizing the importance of vigilant surveillance and multidisciplinary collaboration in optimizing patient outcomes. Further research is needed to understand the mechanisms underlying fibrosarcomatous transformation and to explore novel therapeutic avenues for this challenging malignancy.
  • ||||||||||  Journal:  Case series of the inferior vena cava primary leiomyosarcoma treatment. (Pubmed Central) -  Jun 6, 2024   
    Although a surgical resection combined with the chemotherapy is often not curative, it can achieve a significant long-term survival. For this reason, we recommend the aggressive surgical management using the modern vascular surgical and oncology techniques.
  • ||||||||||  Journal:  Giant cell-rich osteosarcoma of the lumbar spine - A rare entity. (Pubmed Central) -  Jun 6, 2024   
    While it is extremely difficult to distinguish GCRO from malignant giant cell tumour, it is important to do so because of the difference in prognosis and management. Distinctive anatomy of the lumbar spine increases the risks associated with surgical excision.
  • ||||||||||  Journal:  Investigation of a new implant surface modification using phosphorylated pullulan. (Pubmed Central) -  Jun 6, 2024   
    These results are due to the properties of phosphorylated pullulan, such as adhesiveness to titanium and drug-loading function. Therefore, phosphorylated pullulan effectively promotes bone regeneration when coated on titanium implants and is useful for developing a new surface treatment method.
  • ||||||||||  alrizomadlin (APG-115) / Ascentage Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors (clinicaltrials.gov) -  Jun 6, 2024   
    P1/2,  N=95, Recruiting, 
    Therefore, phosphorylated pullulan effectively promotes bone regeneration when coated on titanium implants and is useful for developing a new surface treatment method. Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Apr 2024 --> Apr 2026
  • ||||||||||  Review, Journal:  Extratesticular masses focusing on MRI findings. (Pubmed Central) -  Jun 5, 2024   
    Spermatic cord sarcoma, including rhabdomyosarcoma, leiomyosarcoma, and liposarcoma, and metastasis to the spermatic cord are described as malignant extratesticular masses. This review focused on extratesticular masses and elaborates the imaging findings that can aid in the accurate diagnosis using MRI.
  • ||||||||||  Journal:  A Case of SMARCB1-Deficient Sinonasal Carcinoma With Clear Cell Morphology. (Pubmed Central) -  Jun 5, 2024   
    Simultaneously, the importance of early and accurate diagnosis of SMARCB1-deficient sinonasal carcinoma will increase. With the limited information provided by biopsy specimens, it is necessary to confirm the loss of SMARCB1 expression by immunohistochemistry and investigate the presence of SMARCB1 gene deletion by molecular genetics, considering the possibility of SMARCB1-deficient sinonasal carcinoma even in atypical cases without basaloid or plasmacytoid/rhabdoid cell morphology, as in our case.
  • ||||||||||  pregabalin / Generic mfg., epinephrine / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Journal:  A Novel Approach in Treating Phantom Limb Pain Using Erector Spinae Plane Block. (Pubmed Central) -  Jun 5, 2024   
    In literature, ESP block has been used as a regional technique for shoulder disarticulation surgery and other neuropathic pain conditions, but no account has shown its use for PLP treatment. The procedure was successfully done to alleviate the upper extremity phantom limb pain, significantly reduce analgesic requirements, and improve tolerance of physical therapy and overall quality of life.